Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Early Stage Prostate Cancer Clear all
Completed Phase 2 Interventional Results available

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT01718353
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Acceptance-Based Treatment for Prostate Cancer Distress

NCT01594593
View directory record Official record
Conditions
Early Stage Prostate Cancer
Interventions
Acceptance and Commitment Therapy
Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Pioneering Advances in Care and Education (PACE)

NCT03397160
View directory record Official record
Conditions
Decision Support Systems, Clinical, Prostate Cancer
Interventions
Decision Support Intervention (DSI)
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Palo Alto, California • San Francisco, California • Sartell, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

NCT00151060
View directory record Official record
Conditions
Prostate Cancer
Interventions
Estramustine, Etoposide, Paclitaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

NCT00253383
View directory record Official record
Conditions
Cancer
Interventions
counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

Treatment Decision Making in Early-Stage Prostate Cancer

NCT00196781
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
CD-ROM-based prostate cancer treatment education, CD-ROM-based prostate ca treatment education+decision tools
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
Male only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 23, 2026, 1:32 PM EDT
Completed No phase listed Observational

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

NCT00003329
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
gene mapping
Genetic
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
32
States / cities
Rancho Mirage, California • Fort Collins, Colorado • Boca Raton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

NCT00080808
View directory record Official record
Conditions
Prostate Cancer
Interventions
Alprostadil (E1), Papaverine, Phentolamine mesylate, Sildenafil citrate, conventional surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib

NCT00203424
View directory record Official record
Conditions
Prostate Cancer
Interventions
Erlotinib + Bevacizumab
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
16
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2016 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy

NCT00054522
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone
Dietary Supplement · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Buffalo, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Trial of HIFU vs. Cryo for Prostate Cancer

NCT06929065
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Stage I, Prostate Cancer Stage II, High Intensity Focused Ultrasound, HIFU, Cryoablation
Interventions
HIFU vs Cryoablation
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model

NCT02451345
View directory record Official record
Conditions
Prostate Cancer
Interventions
Personalized risk model+website+coaching intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 23, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

Fulvestrant in Treating Patients With Recurrent Prostate Cancer

NCT00217464
View directory record Official record
Conditions
Prostate Cancer
Interventions
fulvestrant
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

NCT00942578
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Bevacizumab, Lenalidomide, Docetaxel, Prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

NCT00038662
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Atrasentan
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
24
States / cities
Homewood, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00002703
View directory record Official record
Conditions
Prostate Cancer
Interventions
high-LET heavy ion therapy, low-LET photon therapy
Radiation
Lead sponsor
Proton Radiation Oncology Group
Other
Eligibility
Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
2
States / cities
Loma Linda, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 23, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel in Treating Patients With Relapsed Prostate Cancer

NCT00482274
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 23, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

NCT07313241
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Fossa Radiotherapy, Pelvic nodal Radiotherapy, Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

NCT04011410
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
Hydroxychloroquine Sulfate 200Mg Tab
Drug
Lead sponsor
Patrick Hensley
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Not applicable Interventional

LiSWT for Nerve Sparing Radical Prostatectomy ED

NCT05877144
View directory record Official record
Conditions
Erectile Dysfunction, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Nerve-Sparing Prostatectomy, Medical Device Usage and Evaluation, Duplex Ultrasound, Survey Administration, Sham Intervention
Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 23, 2026, 1:32 PM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial

NCT00247312
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Pd-103
Radiation
Lead sponsor
Schiffler Cancer Center
Other
Eligibility
Male only
Enrollment
319 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
2
States / cities
Seattle, Washington • Wheeling, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 23, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors

NCT00078845
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Amifostine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Decatur, Illinois • Urbana, Illinois • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 23, 2026, 1:32 PM EDT